Clinical Trials

Recbio announces Phase III Clinical Trial Progress Of Recombinant HPV 9-Valent Vaccine

The phase III clinical trial of REC603 in China consists of three parts, i.e. the efficacy trial, the immuno-bridging trial in younger-age groups...

 August 11, 2022 | News

Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15

-Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced the initiation of a Phase 3 clinical study, Vacc...

 August 09, 2022 | News

Innovent Biologics and Sanofi Enter Strategic Collaboration to Accelerate Development of Oncology Medicines and Expand Presence in China

Collaboration to accelerate the development and access of oncology medicines for cancer patients in China Clinical trial programs combining two of ...

 August 05, 2022 | News

LG Chem Enters Final Stage of Clinical Development for New Gout Drug

In global Phase 3 clinical trial, Tigulixostat will be evaluated in 350 adult gout patients with hyperuricemia for safety and efficacy at Month 6 of treatm...

 August 04, 2022 | News

Lynk Pharmaceuticals Announces First Participants in Phase I Trial of LNK01004

This study is to evaluate the safety, tolerability, and pharmacokinetics of the LNK01004 ointment in healthy adults and patients with mild to moderate plaq...

 July 29, 2022 | News

Brii Biosciences Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy

Independent lab results demonstrate that the combination therapy retains neutralizing activity against currently dominant COVID-19 strains, as previously d...

 July 27, 2022 | News

DS-7300 Phase 2 Trial Initiated in Patients with Pretreated Extensive-Stage Small Cell Lung Cancer

Lung cancer is the second most common cancer and the leading cause of cancer-related deaths worldwide, with up to 14% being classified as SCLC in the U.S.1...

 July 22, 2022 | News

Daewoong Pharmaceutical Gets First Korean US FDA Fast-Track for New Idiopathic Pulmonary Fibrosis Drug

As many Korean pharmaceutical manufacturers are currently attempting to develop new drugs for idiopathic pulmonary fibrosis, Daewoong Pharmaceutical's new ...

 July 21, 2022 | News

Pulnovo Medical Concludes Successfully First Pre-Sub Meeting with FDA for PADN Global Clinical Trial

Dr. Shaoliang Chen, Chair of Pulnovo Medical's Scientific Advisory Board and pioneer of the PADN technology, attended the meeting and presented the co...

 July 18, 2022 | News

Glenmark Pharmaceuticals and SaNOtize Announce Peer Reviewed Publication of Its Phase 3 Clinical Trials

Glenmark Pharmaceuticals Limited (Glenmark), an innovation-driven, global pharmaceutical company and SaNOtize Research and Development Corp, today announce...

 July 14, 2022 | News

Singapore Based SCG Cell Therapy Announces U.S FDA Clearance

ingapore-based SCG Cell Therapy Pte Ltd ("SCG") announced that U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) ...

 July 12, 2022 | News

Sobi to license loncastuximab tesirine from ADC Therapeutics

Sobi® announced an exclusive license agreement with ADC Therapeutics SA to develop and commercialise loncastuximab tesirine for use in haematology and ...

 July 11, 2022 | News

ZIRCON Phase III Kidney Cancer Imaging Study Completes Enrolment

TLX250-CDx, which has received "Breakthrough Designation" from the U.S. Food and Drug Administration (FDA)1, is being developed as an imaging agent for use...

 July 11, 2022 | News

Vaccizone selects Exothera for process development and GMP manufacturing of its SARS‑CoV‑2 vaccine based on proprietary ASC technology

Vaccizone has developed and patented a novel method for delivering antigens and bioactive compounds which can increase the stability and shelf life of comp...

 July 07, 2022 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close